Salarius Pharmaceuticals (NASDAQ:SLRX) Rating Lowered to Sell at Wall Street Zen

Salarius Pharmaceuticals (NASDAQ:SLRX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Salarius Pharmaceuticals Stock Performance

Shares of NASDAQ SLRX opened at $0.65 on Friday. The company has a market cap of $3.82 million, a P/E ratio of -0.02 and a beta of 0.33. The firm’s fifty day moving average is $1.36 and its two-hundred day moving average is $5.63. Salarius Pharmaceuticals has a 52-week low of $0.62 and a 52-week high of $108.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.81) EPS for the quarter, beating the consensus estimate of ($33.60) by $31.79.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.